title: Comparative proteomic analysis of endothelial cells progenitor cells derived from cord blood- and peripheral blood for cell therapy.
abstract: Vasculopathy due to ischemia in damaged tissues is a major cause of morbidity and mortality. To treat these conditions, endothelial progenitor cells (EPCs) from various sources, such as umbilical cord or peripheral blood, have been the focus of the regenerative medicine field due to their proliferative and vasculogenic activities. However, the fundamental, molecular-level differences between EPCs obtained from different cellular sources have rarely been studied. In this study, we established endothelial progenitor cells derived from cord blood- and peripheral blood (CB- and PB-EPCs) and investigated their fundamental differences at the cellular and molecular levels through a combination of stem cell biology techniques and proteomic analysis. Our results suggest that specifically up-regulated factors such as STMIN 1, CFL 1, PARK 7, NME 1, GLO 1, HSP 27 and PRDX 2 in CB-EPCs as key elements that could be functionally active in ischemic regions. We also discussed functional behaviors important for inducing and maintaining long-lasting blood vessels under ischemic conditions. As a result, CB-EPCs retained a higher anti-oxidant and migration ability than PB-EPCs in vitro. Furthermore, CB-EPCs retained a higher therapeutic efficacy than PB-EPCs in a hindlimb ischemic disease model. The up-regulated expression pattern of STMIN 1, CFL 1, PARK 7, NME 1, GLO 1, HSP 27 and PRDX 2 was confirmed under several conditions in vitro and in vivo, indicating that the up-regulation of these molecules in CB-EPCs may be critical to the mechanism of healing in ischemic conditions and that CB-EPCs may be more appropriate for inducing neo-vessels. Thus, these results may aid in predetermining which cell sources will be of value for cell-based therapies of pathological conditions and identify several candidate molecules that may be involved in the therapeutic mechanism for ischemia.
authors.affiliation: CHA Bio & Diostech Co., Ltd., 606-16 Yeoksam 1 dong, Gangnam gu, Seoul 135-907, Republic of Korea.
authors.forename: Jumi
authors.initials: J
authors.lastname: Kim
authors.forename: Young-Joo
authors.initials: YJ
authors.lastname: Jeon
authors.forename: Hye Eun
authors.initials: HE
authors.lastname: Kim
authors.forename: Jeong Min
authors.initials: JM
authors.lastname: Shin
authors.forename: Hyung Min
authors.initials: HM
authors.lastname: Chung
authors.forename: Jung-Il
authors.initials: JI
authors.lastname: Chae
mesh_terms: D015153:Blotting, Western; D064987:Cell- and Tissue-Based Therapy; D015180:Electrophoresis, Gel, Two-Dimensional; D005312:Fetal Blood / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D040901:Proteomics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013234:Stem Cells / Q000166:cytology / Q000378:metabolism*; D053719:Tandem Mass Spectrometry; D015854:Up-Regulation